Mainz Biomed NV (FRA:4TO) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Mainz Biomed NV Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Mainz Biomed NV's annualized Gross Profit for the quarter that ended in Dec. 2024 was €0.00 Mil. Mainz Biomed NV's average Total Assets over the quarter that ended in Dec. 2024 was €10.25 Mil. Therefore, Mainz Biomed NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.

Mainz Biomed NV Gross-Profit-to-Asset % Historical Data

The historical data trend for Mainz Biomed NV's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mainz Biomed NV Gross-Profit-to-Asset % Chart

Mainz Biomed NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

16.88

3.35

1.23

2.82

4.10

Mainz Biomed NV Quarterly Data
	Dec19	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial									3.06	1.90	3.21	-	-

Competitive Comparison of Mainz Biomed NV's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, Mainz Biomed NV's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mainz Biomed NV's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mainz Biomed NV's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Mainz Biomed NV's Gross-Profit-to-Asset % falls into.

Save Embed

;

Save Embed

;

Mainz Biomed NV Gross-Profit-to-Asset % Calculation

Mainz Biomed NV's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2024 )	/	( (Total Assets (A: Dec. 2023 )	+	Total Assets (A: Dec. 2024 ))	/ count )
	=	0.549	/	( (14.13	+	12.642)	/ 2 )
	=	0.549	/	13.386
	=	4.10 %

Mainz Biomed NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	0	/	( (7.854	+	12.642)	/ 2 )
	=	0	/	10.248
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Mainz Biomed NV Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Mainz Biomed NV's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mainz Biomed NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mainz Biomed NV (FRA:4TO) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

MYNZ:USA

Address

Robert Koch Strasse 50, Sirius Gutenberg Park, Mainz, RP, DEU, 55129

Website

https://www.mainzbiomed.com

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Mainz Biomed NV Headlines

No Headlines